Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection.

Frontiers in immunology - 1 Jan 2026

Xu Hongying, Li Benhua, Yang Jun, Tang Xin

Abstract excerpt

Immune checkpoint inhibitors have improved outcomes in small-cell lung cancer (SCLC), yet durable benefit remains limited, and the immune consequences of SCLC transformation from EGFR-mutant lung adenocarcinoma (LUAD) remain incompletely understood. Conventional explanations for resistance emphasize PD-L1 expression, tumor mutational burden, T-cell dysfunction, myeloid suppression, and stromal exclusion, but...

Read the complete abstract on PubMed

Topics

Humans
Lung Neoplasms
Small Cell Lung Carcinoma
Antigen Presentation
Animals
Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Adenocarcinoma of Lung

Mutation

Cell Lineage

Source

Open in PubMed Open full text

Identifiers

PMID: 42761714
DOI: 10.3389/fimmu.2026.1900927
PMCID: PMC13587010

Genes

EGFR
DLL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection.PMID 42761714Read ↗

Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer.Semantic proximity Read ↗

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.Semantic proximity Read ↗

Persistent lineage plasticity driving lung cancer development and progressionSemantic proximity Read ↗

Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.Semantic proximity Read ↗

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancerSemantic proximity Read ↗

Authentic neuroendocrine transdifferentiation from lung adenocarcinoma to small-cell lung cancer: a case report.Semantic proximity Read ↗

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.Semantic proximity Read ↗

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapySemantic proximity Read ↗

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.Semantic proximity Read ↗

Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers.Semantic proximity Read ↗

Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.Semantic proximity Read ↗

Lineage-specific intolerance to oncogenic drivers restricts histological transformationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.